Q3 Revenue Up 11.5%, Adjusted EBITDA Up 33.6%; Full-Year EBITDA Guidance Raised to $685-695M
PACS has more than doubled off its 52-week low of $10.31.
Summary
PACS beat its own trajectory with Q3 revenue of $1.50 billion, up 11.5%, and Adjusted EBITDA of $175.7 million, up 33.6% — EBITDA growth running roughly three times revenue growth. Adjusted EPS came in at $0.63, up 37.0% year-over-year, while GAAP diluted EPS was $0.37. The bigger news is guidance: management raised full-year 2026 Adjusted EBITDA to $685-695 million from $640-660 million and revenue to $5.95-6.05 billion from $5.75-5.85 billion, with the EBITDA midpoint implying about 37% growth over 2025. That raise includes roughly $5 million of retroactive Ohio quality incentive payments received in October, so a slice of the beat is one-time. Growth is also real on the ground: the 32-facility Florida acquisition closed October 1 and the 11-facility Texas deal closed November 1, pushing the portfolio to 398 operations across 21 states. Cash flow remains strong at $583.1 million from operations through nine months, with $707.4 million of liquidity and net leverage of 0.2x. The earnings call is November 4 at 11:30 a.m. ET.
At the time of this announcement, PACS was trading at $46.68 on NYSE in the Life Sciences sector, with a market capitalization of approximately $7.4B. The 52-week trading range was $10.31 to $50.38. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.